Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572130 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Intravenous Rexin-G in Osteosarcoma
A Phase 2 study, sponsored by Epeius Biotechnologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00572130 is a Phase 2 study that has completed, run by Epeius Biotechnologies. The registered enrollment target is 22 participants.
The verdict
NCT00572130, a Phase 2 study, has completed, sponsored by Epeius Biotechnologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
Rexin-G is a tumor-targeted gene medicine that is designed to seek out and destroy both primary tumors and metastatic cancers without the side effects of standard chemotherapy. The objectives of the study are: (1) to evaluate the clinical effectiveness of intravenous injections of Rexin-G, a tumor-targeted gene vector, in controlling tumor growth and prolonging life, and (2) to evaluate its over-all safety.
Interventions
- GENETIC Rexin-G Dose 1
- GENETIC Rexin-G Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572130
The ClinicalTrials.gov registry entry for NCT00572130 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epeius Biotechnologies, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rexin-G Dose 1 is the first listed.
NCT00572130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00572130 about?
NCT00572130 is a clinical study titled "Phase II Study of Intravenous Rexin-G in Osteosarcoma". Rexin-G is a tumor-targeted gene medicine that is designed to seek out and destroy both primary tumors and metastatic cancers without the side effects of standard chemotherapy. The objectives of the study are: (1) to evaluate the clinical effectiveness of intravenous injections of Rexin-G, a tumor-t...
What is the current status of trial NCT00572130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2007-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00572130?
The interventions under investigation include: Rexin-G Dose 1 (GENETIC), Rexin-G Dose 2 (GENETIC).
Who is sponsoring clinical trial NCT00572130?
This trial is sponsored by Epeius Biotechnologies, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.